Antimycobacterial Drug Discovery and Resistance Mechanisms

Antimycobacterial drug discovery remains a cornerstone of global efforts to control tuberculosis and related infections, challenging researchers to overcome the complex biology of Mycobacterium species. Traditional regimens have become compromised by the emergence of multidrug-resistant and extensively drug-resistant strains, underscoring the urgent need for novel chemical entities, host-directed strategies and drug repurposing approaches. Contemporary pipelines encompass target-based screening against cell-wall biosynthesis enzymes, phenotypic assays for non-replicating persisters and modulation of membrane integrity, all aimed at shortening therapy and mitigating relapse. Resistance mechanisms are diverse, ranging from chromosomal mutations in drug targets and activation of efflux pumps to phenotypic tolerance mediated by dormant subpopulations, necessitating an integrated understanding of bacterial genetics and physiology. Advances in high-throughput genomics and structural biology now inform rational scaffold design and enable early identification of genetic markers of resistance. Collectively, these multidisciplinary efforts strive to deliver effective, safe and accessible antitubercular agents to curb a disease that remains one of the world’s most persistent public-health threats.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Antimycobacterial Drug Discovery and Resistance Mechanisms publication trend

The graph below shows the total number of articles in antimycobacterial drug discovery and resistance mechanisms across all publications each year (not limited to Nature Index journals).

Technical terms

Minimum inhibitory concentration (MIC): Lowest concentration of a compound that prevents visible bacterial growth.
Multidrug-resistant (MDR): Strains resistant to at least isoniazid and rifampicin, the two most potent first-line drugs.
Persister cells: Non-replicating bacterial subpopulations that survive lethal drug concentrations without genetic resistance.
Scaffold: Core molecular framework of a series of compounds that guides chemical modifications to improve activity.
Efflux pump: Membrane-associated protein complexes that extrude antibiotics, reducing intracellular drug accumulation.

References

1. Novel Derivatives of Quinoxaline-2-carboxylic Acid 1,4-Dioxides as Antimycobacterial Agents: Mechanistic Studies and Therapeutic Potential. Pharmaceuticals (2023).
2. Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches. Frontiers in Microbiology (2024).
3. Periphery Exploration around 2,6-Diazaspiro[3.4]octane Core Identifies a Potent Nitrofuran Antitubercular Lead. Molecules (2023).
4. The Mycobacterial Membrane: A Novel Target Space for Anti-tubercular Drugs. Frontiers in Microbiology (2018).